Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer

Supporting evidence

• Evaluation report

• Final appraisal determination committee papers (PDF 988 KB)

  Published:

  03 August 2022

• Appraisal consultation committee papers (PDF 7.19 MB)

  Published:

  03 August 2022